Cargando…

Lipoprotein-Associated Phospholipase A(2) Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study

OBJECTIVE: To investigate the association of lipoprotein-associated phospholipase A(2) (LpPLA(2)) mass and activity with incident cardiovascular disease (CVD) in a population with high prevalences of insulin resistance and diabetes, conditions for which epidemiological data remain sparse. RESEARCH D...

Descripción completa

Detalles Bibliográficos
Autores principales: Kizer, Jorge R., Umans, Jason G., Zhu, Jianhui, Devereux, Richard B., Wolfert, Robert L., Lee, Elisa T., Howard, Barbara V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308309/
https://www.ncbi.nlm.nih.gov/pubmed/22338104
http://dx.doi.org/10.2337/dc11-1639
_version_ 1782227422346739712
author Kizer, Jorge R.
Umans, Jason G.
Zhu, Jianhui
Devereux, Richard B.
Wolfert, Robert L.
Lee, Elisa T.
Howard, Barbara V.
author_facet Kizer, Jorge R.
Umans, Jason G.
Zhu, Jianhui
Devereux, Richard B.
Wolfert, Robert L.
Lee, Elisa T.
Howard, Barbara V.
author_sort Kizer, Jorge R.
collection PubMed
description OBJECTIVE: To investigate the association of lipoprotein-associated phospholipase A(2) (LpPLA(2)) mass and activity with incident cardiovascular disease (CVD) in a population with high prevalences of insulin resistance and diabetes, conditions for which epidemiological data remain sparse. RESEARCH DESIGN AND METHODS: We conducted a nested, case-control study (n = 1,008) within a population-based cohort of American Indians. Case subjects were defined by incidence of first-ever CVD up to 10 years later. Control subjects comprised participants free of CVD events during the follow-up period who were frequency matched to case subjects by age, sex, and diabetes status. LpPLA(2) mass and activity were measured using commercially available assays. RESULTS: LpPLA(2) mass and activity were moderately correlated with each other (r = 0.30), but only LpPLA(2) activity exhibited moderate correlations with lipid fractions. After extensive adjustment for covariates, both LpPLA(2) measures were significantly associated with incident CVD, but the relationship was inverse for LpPLA(2) mass (highest versus lowest tertile, relative risk [RR] 0.55 [95% CI 0.39–0.79]) and positive for LpPLA(2) activity (highest versus lowest tertile, 1.65 [1.12–2.42]). These associations were similar when participants with and without diabetes were examined separately. CONCLUSIONS: In this population-based cohort enriched with dysmetabolic phenotypes, LpPLA(2) mass and activity showed divergent associations with CVD. The inverse relationship for LpPLA(2) mass is contrary to observations from predominantly nondiabetic populations and will require independent replication. Whether this finding relates to redistribution of LpPLA(2) to lipoprotein classes where it is less atherogenic or reflects incomplete measurement of LpPLA(2) mass associated with altered lipoprotein composition in insulin resistance warrants further investigation.
format Online
Article
Text
id pubmed-3308309
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-33083092013-04-01 Lipoprotein-Associated Phospholipase A(2) Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study Kizer, Jorge R. Umans, Jason G. Zhu, Jianhui Devereux, Richard B. Wolfert, Robert L. Lee, Elisa T. Howard, Barbara V. Diabetes Care Original Research OBJECTIVE: To investigate the association of lipoprotein-associated phospholipase A(2) (LpPLA(2)) mass and activity with incident cardiovascular disease (CVD) in a population with high prevalences of insulin resistance and diabetes, conditions for which epidemiological data remain sparse. RESEARCH DESIGN AND METHODS: We conducted a nested, case-control study (n = 1,008) within a population-based cohort of American Indians. Case subjects were defined by incidence of first-ever CVD up to 10 years later. Control subjects comprised participants free of CVD events during the follow-up period who were frequency matched to case subjects by age, sex, and diabetes status. LpPLA(2) mass and activity were measured using commercially available assays. RESULTS: LpPLA(2) mass and activity were moderately correlated with each other (r = 0.30), but only LpPLA(2) activity exhibited moderate correlations with lipid fractions. After extensive adjustment for covariates, both LpPLA(2) measures were significantly associated with incident CVD, but the relationship was inverse for LpPLA(2) mass (highest versus lowest tertile, relative risk [RR] 0.55 [95% CI 0.39–0.79]) and positive for LpPLA(2) activity (highest versus lowest tertile, 1.65 [1.12–2.42]). These associations were similar when participants with and without diabetes were examined separately. CONCLUSIONS: In this population-based cohort enriched with dysmetabolic phenotypes, LpPLA(2) mass and activity showed divergent associations with CVD. The inverse relationship for LpPLA(2) mass is contrary to observations from predominantly nondiabetic populations and will require independent replication. Whether this finding relates to redistribution of LpPLA(2) to lipoprotein classes where it is less atherogenic or reflects incomplete measurement of LpPLA(2) mass associated with altered lipoprotein composition in insulin resistance warrants further investigation. American Diabetes Association 2012-04 2012-03-13 /pmc/articles/PMC3308309/ /pubmed/22338104 http://dx.doi.org/10.2337/dc11-1639 Text en © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
Kizer, Jorge R.
Umans, Jason G.
Zhu, Jianhui
Devereux, Richard B.
Wolfert, Robert L.
Lee, Elisa T.
Howard, Barbara V.
Lipoprotein-Associated Phospholipase A(2) Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study
title Lipoprotein-Associated Phospholipase A(2) Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study
title_full Lipoprotein-Associated Phospholipase A(2) Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study
title_fullStr Lipoprotein-Associated Phospholipase A(2) Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study
title_full_unstemmed Lipoprotein-Associated Phospholipase A(2) Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study
title_short Lipoprotein-Associated Phospholipase A(2) Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study
title_sort lipoprotein-associated phospholipase a(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the strong heart study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308309/
https://www.ncbi.nlm.nih.gov/pubmed/22338104
http://dx.doi.org/10.2337/dc11-1639
work_keys_str_mv AT kizerjorger lipoproteinassociatedphospholipasea2massandactivityandriskofcardiovasculardiseaseinapopulationwithhighprevalencesofobesityanddiabetesthestrongheartstudy
AT umansjasong lipoproteinassociatedphospholipasea2massandactivityandriskofcardiovasculardiseaseinapopulationwithhighprevalencesofobesityanddiabetesthestrongheartstudy
AT zhujianhui lipoproteinassociatedphospholipasea2massandactivityandriskofcardiovasculardiseaseinapopulationwithhighprevalencesofobesityanddiabetesthestrongheartstudy
AT devereuxrichardb lipoproteinassociatedphospholipasea2massandactivityandriskofcardiovasculardiseaseinapopulationwithhighprevalencesofobesityanddiabetesthestrongheartstudy
AT wolfertrobertl lipoproteinassociatedphospholipasea2massandactivityandriskofcardiovasculardiseaseinapopulationwithhighprevalencesofobesityanddiabetesthestrongheartstudy
AT leeelisat lipoproteinassociatedphospholipasea2massandactivityandriskofcardiovasculardiseaseinapopulationwithhighprevalencesofobesityanddiabetesthestrongheartstudy
AT howardbarbarav lipoproteinassociatedphospholipasea2massandactivityandriskofcardiovasculardiseaseinapopulationwithhighprevalencesofobesityanddiabetesthestrongheartstudy